We are live on
!
Find out more
BCM
BML Capital Management Portfolio holdings
AUM
$176M
1-Year Est. Return
123.21%
This Fund
S&P 500
This Quarter
Est. Return
+26.33%
1 Year Est. Return
+123.21%
3 Year Est. Return
+348.91%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$6.47M
(+5.9%)
Cap. Flow
-$11.4M
Cap. Flow
% of AUM
-9.89%
Top 10 Holdings %
Top 10 Hldgs %
95.6%
Holding
25
New
5
Increased
3
Reduced
3
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CarMax
KMX
|
+$6.2M |
| 2 |
Outset Medical
OM
|
+$4.66M |
| 3 |
Target
TGT
|
+$2.53M |
| 4 |
Pliant Therapeutics
PLRX
|
+$2.32M |
| 5 |
Atea Pharmaceuticals
AVIR
|
+$51K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADVM
Adverum Biotechnologies
ADVM
|
+$13.9M |
| 2 |
ALMS
Alumis Inc
ALMS
|
+$4.83M |
| 3 |
LVTX
LAVA Therapeutics
LVTX
|
+$3.07M |
| 4 |
CNTB
Connect Biopharma Holdings
CNTB
|
+$1.83M |
| 5 |
LONA
LeonaBio Inc
LONA
|
+$1.34M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.31% |
| 2 | Consumer Discretionary | 5.18% |
| 3 | Consumer Staples | 3.17% |
| 4 | Miscellaneous | 2.35% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Aclaris Therapeutics
ACRS
$908M
| $42.9M | 37.08% |
14,250,000
| – | – |
|
|
2
Atea Pharmaceuticals
AVIR
$468M
| $26.7M | 23.11% |
7,490,000
+16,037
| +0.2% | +$51K |
|
3
Oramed Pharmaceuticals
ORMP
$208M
| $9.03M | 7.8% |
3,167,231
| – | – |
|
4
Instil Bio
TIL
$51.4M
| $7.1M | 6.14% |
645,600
| – | – |
|
5
PMV Pharmaceuticals
PMVP
$69M
| $6.62M | 5.72% |
5,292,000
| – | – |
|
|
6
CarMax
KMX
$8.98B
| $5.99M | 5.18% |
+155,000
| New | +$6.2M |
|
|
KZR
7
DELISTED
Kezar Life Sciences
KZR
| $4.53M | 3.92% |
720,787
| – | – |
|
|
8
Target
TGT
$74.7B
| $3.67M | 3.17% |
37,500
+27,500
| +275% | +$2.53M |
|
9
PUT
Carvana
CVNA
$53.7B
| $2.02M | 1.74% |
+750
| New | +$55.8K |
|
|
10
Outset Medical
OM
$67.5M
| $2.02M | 1.74% |
+543,180
| New | +$4.66M |
|
|
11
Pliant Therapeutics
PLRX
$71.8M
| $1.89M | 1.63% |
+1,546,137
| New | +$2.32M |
|
|
IMA
12
ImageneBio Inc
IMA
$55.1M
| $1.22M | 1.06% |
177,026
-5,483
| -3% | -$40.7K |
|
|
CNTB
13
Connect Biopharma Holdings
CNTB
$116M
| $1.15M | 1% |
408,887
-858,613
| -68% | -$1.83M |
|
14
PUT
Walmart Inc
WMT
$850B
| $492K | 0.43% |
335
+70
| +26% | +$7.52K |
|
15
PUT
Tesla
TSLA
$1.4T
| $205K | 0.18% |
+1,000
| New | +$443K |
|
16
Lisata Therapeutics
LSTA
$14.9M
| $136K | 0.12% |
73,348
-36,493
| -33% | -$81.1K |
|
|
ADVM
17
DELISTED
Adverum Biotechnologies
ADVM
| – | – |
-3,057,526
| Closed | -$13.9M |
|
18
Arvinas
ARVN
$614M
| – | – |
-50,000
| Closed | -$426K |
|
19
Astrotech Corp
ASTC
$15.5M
| – | – |
-220,410
| Closed | -$1.08M |
|
|
LONA
20
LeonaBio Inc
LONA
$71.2M
| – | – |
-323,066
| Closed | -$1.34M |
|
|
LVTX
21
DELISTED
LAVA Therapeutics
LVTX
| – | – |
-1,970,610
| Closed | -$3.07M |
|
|
MURA
22
DELISTED
Mural Oncology
MURA
| – | – |
-57,500
| Closed | -$119K |
|
|
THRD
23
DELISTED
Third Harmonic Bio
THRD
| – | – |
-3,824,417
| Closed | – |
|
24
VistaGen Therapeutics
VTGN
$10.8M
| – | – |
-150,000
| Closed | -$533K |
|
|
ALMS
25
Alumis Inc
ALMS
$1.44B
| – | – |
-1,210,415
| Closed | -$4.83M |
|
Similar funds
LFA
BMCM
KRAVCF
CC
ADMI
DF
OL
MP
BML Capital Management's Q4 2025 Portfolio in Review
As of Q4 2025, BML Capital Management held 25 positions worth $116M, up 5.9% from $109M the previous quarter. Its ten largest holdings account for 96% of the portfolio.
BML Capital Management withdrew a net $11.4M in Q4 2025, closing 9 positions and reducing 3 holdings. Its most notable exit was Adverum Biotechnologies, an estimated $13.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 98% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
Against the trend, BML Capital Management opened a new position in CarMax worth $5.99M.
- BML Capital Management's largest Q4 2025 buy was CarMax: 155,000 shares worth $5.99M.
- BML Capital Management added most to Target in Q4 2025, an estimated $2.53M increase.
- BML Capital Management's biggest Q4 2025 reduction was Connect Biopharma Holdings, cutting an estimated $1.83M.
- BML Capital Management fully exited Adverum Biotechnologies in Q4 2025, selling an estimated $13.9M.
- BML Capital Management's ten largest holdings make up 96% of its $116M portfolio in Q4 2025.
- BML Capital Management opened 5 new positions and closed 9 in Q4 2025.
- BML Capital Management's portfolio value rose 5.9% quarter-over-quarter to $116M.
Based on BML Capital Management's 13F filing for Q4 2025, filed 3 Feb 2026.